Navigation Links
For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Date:12/17/2009

er treatments with Traditional Chinese Medicine (TCM) and cell therapies.

The role of cancer stem cells in the tumors

Scientists previously believed that tumors are lumps of cancer tissue that must be completely removed or destroyed to cure a patient. But over the past few years, researchers have learned that cancer stem cells (CSCs), comprising a small population of cells, appear to be responsible for the initiation, upkeep and relapse of malignant tumors. Even if a tumor is almost completely obliterated, it will regenerate from the surviving CSCs and become even more resistant to treatment than before.

Current therapies, including cell therapy, generally do not target CSCs. This allows CSCs to survive until after chemotherapy or radiation treatments. Killing those cells is a promising strategy to eliminate tumors and prevent them from re-growing.

Prof. Lily Shum: Perfect integration of stem cells and immunotherapies

"The CSCs may explain why common treatments, particularly chemotherapy, are not sufficient to kill tumors. In fact, despite the continuous development of new chemotherapeutic agents, brain tumors can develop and remain resistant to those therapies. The integration of stem cells and immune technologies seems to give us a chance to find out a new way to target at CSCs," says Prof. Lily Shum, PhD, the chief scientist of Cellonis.

"The difficult issue in our project is how to capture and classify CSCs. With our patented technologies, we are able to isolate the CSCs from patient's brain tumor tissues, culture them and induce the multi-drug and radiation resistance. These cells possess very strong carcinogenicity, self-renewal, and also a very strong drug and radiation resistance."

Lily Shum adds, "The Dendritic Cell (DC) is a very useful tool to conduct a specific immune response against brain CSCs." As we know, DC is an antigen-presenting cell
'/>"/>

SOURCE Cellonis Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Orthobiologics are substances that are ... orthobiologics market is a rewarding market, which represents a ... orthobiologics market report defines and segments the concerned market ... market was valued at $5,712.4 million in 2014, and ... a CAGR of 6.7% from 2014 to 2019. ...
(Date:4/20/2015)... -- - Development of a Novel Taxane ... Platform - To be Presented on Tuesday, Apr 21, ... of Antibody-drug Conjugates Using an anti-HER2 Monoclonal Antibody and ... 19, 1:00 PM EST Invictus Oncology Private ... that the company,s novel computational platform technology (VOLVOX) for ...
(Date:4/20/2015)... Whitehouse Laboratories is pleased and overly excited to announce ... Drug Administration (FDA) inspection and received no observations and ... inspection, as based upon 21CFR Parts 210 and 211 ... was granted NAI (no action indicated) status. The inspection ... Practice (GMP) quality system required by the regulatory agency. ...
(Date:4/17/2015)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), ... and commercializes proprietary technologies and products for advanced ... received approval from the TSX Venture Exchange to ... purchase warrants ("the Warrants") of the Company, which ... 2013 private placement financing. Each Warrant ...
Breaking Biology Technology:Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3
... Commercialization and Supply Agreement, Company to Host Conference Call at 12:30 p.m. ... ... 2007, LEXINGTON, Mass., Sept. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... acquisition of Esprit Pharma, has obtained the,United States rights to SANCTURA(R) and ...
... Ventures, Kleiner Perkins ... Ventures, Strong Endorsement of Technology Pioneer at Forefront of Developing No- ... Compromise Biofuels, ... renewable hydrocarbon biofuels, today,announced that it closed the first tranche of its $70 ...
... - IDF Launches New Guideline for the ... the new global guideline for diabetes care which,includes ... people with diabetes should have their blood glucose ... diabetes control and reduce the,risk of complications, particularly ...
Cached Biology Technology:Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6Amyris Biotechnologies Announces $70 Million Series B Round 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 3
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
(Date:3/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces its biometric ... the products featured in 2015 "I Want That" International ... EST on the DIY Network.   DIY,s ... , site of the 2015 International CES for ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... at the core of biomedical research, allowing scientists to study ... In the ideal, such models accurately recapitulate a ... in a rat model would be virtually indistinguishable from that ... rats aren,t human, and few models actually faithfully reflect the ...
... release is available in German . Proteins ... applications in life science research, biotechnology and medicine. So how ... attain certain desired properties? In the past, the modifications were ... team of Professor Arne Skerra from the TUM Chair of ...
... let the bedbugs bite" is becoming an impossible dream ... resurgence of an ancient scourge that is fostering human ... potentially toxic materials. That,s the message from the cover ... News (C&EN), ACS, weekly newsmagazine. In the article, ...
Cached Biology News:What's in a name? Broadening the biological lexicon to bolster translational research 2What's in a name? Broadening the biological lexicon to bolster translational research 3Synthetic biology: TUM researchers develop novel kind of fluorescent protein 2
96 Well Plate UB, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Black 96 Well Plate EB, RE Bottom...
96 Well Plate EB, RE bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes. Guaranteed coefficient of variation (CVs)....
...
Biology Products: